行情

NBIX

NBIX

神经分泌生物科学
NASDAQ

实时行情|Nasdaq Last Sale

98.86
-0.31
-0.31%
交易中 15:12 01/27 EST
开盘
98.01
昨收
99.17
最高
99.38
最低
97.58
成交量
29.46万
成交额
--
52周最高
119.65
52周最低
71.85
市值
91.04亿
市盈率(TTM)
585.32
分时
5日
1月
3月
1年
5年

分析师评级

19位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NBIX 新闻

  • Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results
  • PR Newswire.6天前
  • Zacks.com featured highlights include: Zumiez, Neurocrine Biosciences and Covanta
  • Zacks.01/20 15:02
  • Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $121
  • Benzinga.01/17 13:28
  • Look Beyond Earnings Growth, Tap the Beat With These 3 Stocks
  • Zacks.01/17 13:22

更多

所属板块

生物技术和医学研究
-0.71%
制药与医学研究
-0.34%

热门股票

名称
价格
涨跌幅

NBIX 简况

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.
展开

Webull提供Neurocrine Biosciences, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。